Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models [0.03%]
高效拮抗人肥大细胞和疾病模型中的MAS相关G蛋白偶联受体X2/B2的亚纳摩尔竞争性拮抗剂
Ghazl Al Hamwi,Mohamad Wessam Alnouri,Sven Verdonck et al.
Ghazl Al Hamwi et al.
The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 a...
IL-27: overclocking cytotoxic T lymphocytes to boost cancer immunotherapy [0.03%]
IL-27：通过促进细胞毒性T淋巴细胞来增强癌症免疫治疗
Silvia Dusi,Vincenzo Bronte,Francesco De Sanctis
Silvia Dusi
Junling Ren,Guangli Yan,Le Yang et al.
Junling Ren et al.
Although cancer chemopreventive agents have been confirmed to effectively protect high-risk populations from cancer invasion or recurrence, only over ten drugs have been approved by the U.S. Food and Drug Administration. Therefore, screenin...
RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer [0.03%]
RNase1介导的ALK激活是非小细胞肺癌中的致癌驱动因素和治疗靶点
Zhengyu Zha,Chunxiao Liu,Meisi Yan et al.
Zhengyu Zha et al.
Targeted therapy has achieved significant success in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring common oncogenic driver mutations such as EGFR, KRAS, and ALK rearrangement. However, ~35-50% of NS...
Jiali Nie,Ling Zhou,Weiwei Tian et al.
Jiali Nie et al.
Cytokine storm (CS) is a severe systemic inflammatory syndrome characterized by the excessive activation of immune cells and a significant increase in circulating levels of cytokines. This pathological process is implicated in the developme...
Stephen V Liu,Misako Nagasaka,Judith Atz et al.
Stephen V Liu et al.
Oncogenic gene fusions occur across a broad range of cancers and are a defining feature of some cancer types. Cancers driven by gene fusion products tend to respond well to targeted therapies, where available; thus, detection of potentially...
Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial [0.03%]
CD147单抗美普兰乌马布治疗重症新冠患者的双盲、随机、安慰剂对照III期临床试验
Huijie Bian,Liang Chen,Zheng Zhang et al.
Huijie Bian et al.
Meplazumab, a humanized CD147 antibody, showed favorable safety and clinical benefits in phase 1 and phase 2/3 seamless clinical studies. Further evaluation of its therapeutic efficacy in patients with severe COVID-19 is needed. In this pha...
Correction: Overexpression of CIP2A is associated with poor prognosis in multiple myeloma [0.03%]
关于CIP2A过表达与多发性骨髓瘤预后不良关联的更正通知
Xuewen Liu,Wei Cao,Shanshan Qin et al.
Xuewen Liu et al.
Novel derivatives of brincidofovir and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine inhibit orthopoxviruses and human adenoviruses more potently than brincidofovir [0.03%]
新型溴西多福韦和(S)-9-(3-羟基-2-磷甲氧基丙基)腺嘌呤衍生物比溴西多福韦更能够抑制正痘病毒和人类腺病毒
Yifan Zhang,Yanmin Wan,Cuiyuan Guo et al.
Yifan Zhang et al.
Brincidofovir (BCV) and tecovirimat are the only two chemical drugs that have been approved to treat smallpox and can be requested for monkeypox (Mpox) treatment through a single-patient Emergency Investigational New Drug (EIND) application...